Rheumatic IRAEs from checkpoint inhibitor therapy are growing rapidly in scope and rheumatologists must be aware of these complications, as they are certain to encounter this type of patient.
Dr. Jack Cush: CRIB Study: Transplacental Non-transfer of CZP
Dr. Jack Cush is at EULAR 2017 and is reporting on the CRIB study.
Dr. Cassie Calabrese: Immune-related Adverse Events with Checkpoint Inhibitors
Dr. Cassie Calebrese is live from EULAR 2017 discussing the balance between autoimmunity and cancer.
The current Lancet edition for 10 June 2017 is a rheumatology rich collection. The editorial profiles this years European League Against Rheumatism (EULAR) Annual Congress, that will begin on Wednesday June 14, 2017. This is a highlight year as EULAR celebrates its 70th anniversary.
Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.
On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.
Subcutaneous (SC) abatacept (Orencia) is now available for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic (JIA) according to Bristol-Myers Squibb. Orencia was previously approved for use in adults with rheumatoid arthritis (RA) and was FDA approved for pediatric use in March 2017.
Dr. Olga Petryna: Cardiovascular risk and Takayasu's arteritis
Dr. Petryna discusses a retrospective study on cardiovascular event risk for patients with Takayasu's arteritis presented at the ACR/ARHP Annual Scientific Meeting.
Just last week, I went to a doctor’s retirement party. It was festive, with honors and ribbing for the lucky one, but there was an asterisk to his milestone. Retirement was not anticipated or planned for. What is your retirement plan?
Vaccinating our rheumatoid arthritis patients against influenza every year is a safety priorty. However immunosuppressive therapies pose a challenge to vaccine administration as their use can hamper vaccine immunogenicity.
Dr. Jack Cush reviews the news and reports of interest from RheumNow in the last week:
The U.S. Food and Drug Administration has asked Endo International to withdraw Opana ER from the market, stating that benefits no longer outweigh its risks of this long-acting opioid.A March 2017 advisory committee concluded that Opana ER, is not safe, and many have called for its removal.Opana ER is twice as potent as oxycodone and has a high abuse potential when crushed and taken for a massive high effect by addicts.
Drs. Kremer and Weinblatt have responded to a recent Annals of Rheumatic Disease article regarding the hepatic risks of alcohol use with methotrexate (MTX) therapy authored by Humphries et al. (Citation source: http://buff.ly/2r70uuz)
The American College of Rheumatology has updated its 2010 guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. The guideline provides recommendations on assessing fracture risk and treatment for adults and special patient populations, including women of childbearing potential, adults treated with very high-dose glucocorticoids, adults with organ transplants, and children ages 4-17.
